Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052198 | 1.00 | MEN1 (0.32) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3306442 | 0.98 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1 | |
| SCHEMBL10391901 | 0.98 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1 | |
| SCHEMBL3310877 | 0.86 | L3MBTL1 (0.38) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL9326584 | 0.86 | L3MBTL1 (0.38) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL9326645 | 0.85 | FAAH (0.43) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3307530 | 0.84 | TSHR (0.39) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL9870660 | 0.84 | TSHR (0.39) | MEN1KMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL9225054 | 0.83 | FAAH (0.47) | — | |
| SCHEMBL9225064 | 0.83 | FAAH (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| EP-0473208-B1 | Liquid crystal compounds containing a pyrazine or pyridine ring | MERCK PATENT GMBH (DE) | 1995-03-15 | — | — | EP | disclosed |
| EP-0252961-B1 | HETEROCYCLIC COMPOUNDS AS COMPONENTS OF LIQUID CRYSTAL PHASES | MERCK PATENT GMBH (DE) | 1995-02-08 | — | — | EP | disclosed |
| EP-0361157-B1 | Phenyl pyridines | HOFFMANN LA ROCHE (CH) | 1994-03-02 | — | — | EP | disclosed |
| US-5284956-A | Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines | HOFFMANN-LA ROCHE INC. (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0473208-A2 | Liquid crystal compounds containing a pyrazine or pyridine ring | MERCK PATENT GmbH (DE) | 1992-03-04 | — | — | EP | disclosed |
| EP-0361157-A1 | Phenyl pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1990-04-04 | — | — | EP | disclosed |
| US-4913837-A | Heterocyclic compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-04-03 | — | — | US | disclosed |
| WO-1987004158-A2 | HETEROCYCLIC COMPOUNDS AS COMPONENTS OF LIQUID CRYSTAL PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-07-16 | — | — | WO | disclosed |
| US-3932404-A | REACTION WITH AMMONIA AND A BASIC AGENT | PECHINEY UGINE KUHLMANN (FR) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | MEN1 1636/4885KMT2A 1778/4885TDP1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.